The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…
Tandem Diabetes Care’s (TNDM) latest trip to the capital markets reads less like a distress signal and more like a company quietly extending its runway in a race it fully intends to finish. At the same time, a familiar name in diabetes…
Insulet’s (PODD) latest numbers read like the balance sheet of a very determined racehorse: fast, disciplined, and still eager for the next lap, even as a promising upstart named Modular Medical trots onto the same track.
Insulet’s Earnings: Hitting a Full Gallop…
Modular Medical’s (NASDAQ: MODD) Pivot insulin delivery system is quietly building a credible bull case that now extends beyond regulatory momentum and leadership credentials into hard operational execution. With the company achieving a key manufacturing milestone for its Pivot tubeless insulin patch…
